BD announces senior management changes
Mr Forlenza and Mr Elkins will both report to Edward Ludwig, who will remain as chairman and CEO. John Considine will remain as vice chairman. As president, Mr
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.